Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation

Pharmacological Research

Volumn 56, Issue 6, 2007, Pages 503-508

  Arnaboldi, Lorenzo ^a   Guzzetta, Massimiliano ^a   Pazzucconi, Franco ^a   Radaelli, Giovanni ^a   Paoletti, Rodolfo ^a   Sirtori, Cesare R ^a   Corsini, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; Cell proliferation; Hypercholesterolemia; Pleiotropic effects of statins

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOOTH MUSCLE FIBER;

ADULT; AGED; CELL LINE; CELL PROLIFERATION; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FEMORAL ARTERY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; PYRROLES; SERUM; SIMVASTATIN;

EID: 36248976098     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.09.012     Document Type: Article

References (29)

1. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
2. Mahley R.W., and Bersot T.P. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. (2006), McGraw Hill, New York 933-966
3. Cignarella A., Bellosta S., Corsini A., Bolego C., et al. Hypolipidemic therapy for the metabolic syndrome. Pharmacol Res 53 (2006) 492-500
4. Haramaki N., Ikeda H., Takenaka K., et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 27 (2007) 1471-1477
5. Ray K.K., Cannon C.P., and Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials?. Am J Cardiol 98 (2006) 18P-25P
6. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45 (2005) 89-118
7. Corsini A., Bellosta S., Baetta R., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84 (1999) 413-428
8. Tobert J.A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. In Nat Rev Drug Discov (2003) 517-526
9. Corsini A., Pazzucconi F., Arnaboldi L., et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 31 (1998) 773-778
10. Corsini A., Pazzucconi F., Pfister P., et al. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet 348 (1996) 1584
11. Martinez-Gonzalez J., and Badimon L. Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: implication for in vivo interventions in the porcine model. Eur J Clin Invest 26 (1996) 1023-1032
12. Raiteri M., Arnaboldi L., McGeady P., et al. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 281 (1997) 1144-1153
13. Soma M.R., Donetti E., Parolini C., et al. HMG CoA reductase inhibitors, In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 13 (1993) 571-578
14. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
15. Glomset J.A., and Farnsworth C.C. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol 10 (1994) 181-205
16. Bellosta S., Arnaboldi L., Gerosa L., et al. Statins effect on smooth muscle cell proliferation. Semin Vasc Med 4 (2004) 347-356
17. Monetti M., Canavesi M., Camera M., et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res 55 (2007) 441-449
18. Bjorkhem I., Miettinen T., Reihner E., et al. Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J Lipid Res 28 (1987) 1137-1143
19. Naoumova R.P., Dunn S., Rallidis L., et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 38 (1997) 1496-1500
20. Saisho Y., Morimoto A., and Umeda T. Determination of farnesyl pyrophosphate in dog and human plasma by high-performance liquid chromatography with fluorescence detection. Anal Biochem 252 (1997) 89-95
21. Cilla Jr. D.D., Whitfield L.R., Gibson D.M., et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 60 (1996) 687-695
22. Speidel M.T., Booyse F.M., Abrams A., et al. Lipolyzed hypertriglyceridemic serum and triglyceride-rich lipoprotein cause lipid accumulation in and are cytotoxic to cultured human endothelial cells, High density lipoproteins inhibit this cytotoxicity. Thromb Res 58 (1990) 251-264
23. Rogers S.L., Magliano D.J., Levison D.B., et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther 29 (2007) 242-252
24. Tsimikas S., Witztum J.L., Miller E.R., et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110 (2004) 1406-1412
25. Tong H., Holstein S.A., and Hohl R.J. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal Biochem 336 (2005) 51-59
26. Baldassarre D., Veglia F., Gobbi C., et al. Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. Atherosclerosis 151 (2000) 575-583
27. Shitara Y., and Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112 (2006) 71-105
28. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
29. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696